save
date
oxurion
host
virtual
r
investor
day
october
save
date
oxurion
host
virtual
r
investor
day
october
leuven
belgium
october
cet
oxurion
nv
euronext
brussels
oxur
biopharmaceutical
company
developing
next
generation
therapies
diabetic
macular
edema
dme
host
virtual
r
investor
day
october
cet
bst
et
meeting
intended
investors
analysts
provide
overview
company
development
pipeline
corporate
strategy
focused
successfully
creating
industry
leading
dme
franchise
oxurion
currently
developing
two
novel
drug
candidates
modes
action
together
potential
deliver
new
standard
care
patients
dme
presentations
delivered
members
oxurion
senior
management
team
two
global
key
opinion
leaders
field
retinal
vascular
disorders
ramin
tadayoni
professor
ophthalmology
university
paris
head
ophthalmology
departments
lariboisière
st
louis
rothschild
foundation
hospitals
paris
france
professor
ophthalmology
university
paris
head
ophthalmology
departments
lariboisière
st
louis
rothschild
foundation
hospitals
paris
france
arshad
khanani
managing
partner
director
clinical
research
director
fellowship
sierra
eye
associates
clinical
associate
professor
university
nevada
reno
us
agenda
details
join
meeting
available
invitation
company
website
issued
closer
time
event
end
information
please
contact
oxurion
nv
wouter
piepers
global
head
investor
relations
corporate
communications
tel
citigate
dewe
rogerson
david
dible
sylvie
berrebi
frazer
hall
tel
oxurion
oxurion
oxurion
euronext
brussels
oxur
biopharmaceutical
company
developing
next
generation
standard
care
ophthalmic
therapies
designed
better
preserve
vision
patients
diabetic
macular
edema
dme
leading
cause
vision
loss
diabetic
patients
worldwide
oxurion
building
leading
global
franchise
treatment
dme
based
successful
development
two
novel
therapeutics
plasma
kallikrein
inhibitor
developed
potential
new
standard
care
dme
patients
respond
therapy
shown
positive
topline
phase
results
treatment
dme
company
currently
conducting
phase
clinical
trial
evaluating
previously
responded
therapy
developed
conjunction
bicycle
therapeutics
plc
nasdaq
bcyc
integrin
inhibitor
initially
developed
potential
new
standard
care
dme
patients
positive
topline
results
phase
clinical
study
assessing
treatment
dme
announced
january
expected
enter
phase
clinical
trial
optimized
compound
derived
broader
library
integrin
inhibitors
galapagos
nv
euronext
nasdaq
glpg
oxurion
headquartered
leuven
belgium
listed
euronext
brussels
exchange
symbol
oxur
information
available
important
information
statements
certain
statements
press
release
may
considered
statements
based
current
expectations
accordingly
entail
influenced
various
risks
uncertainties
company
therefore
provide
assurance
statements
materialize
assume
obligation
update
revise
statement
whether
result
new
information
future
events
reason
additional
information
concerning
risks
uncertainties
affecting
business
factors
could
cause
actual
results
differ
materially
statement
contained
company
annual
report
press
release
constitute
offer
invitation
sale
purchase
securities
assets
oxurion
jurisdiction
securities
oxurion
may
offered
sold
within
united
states
without
registration
securities
act
amended
compliance
exemption
therefrom
accordance
applicable
state
securities
laws
